{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-011852","form_type":"8-K","ticker":null,"cik":"0001783032","company_name":"Elevation Oncology, Inc.","filed_at":"2023-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.214514+00:00","generated_at":"2026-06-13T08:50:29.605632+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Elevation Oncology appoints Joseph Ferra as permanent CEO and Tammy Furlong as CFO","bullets":["Joseph J. Ferra Jr. appointed President & CEO effective July 12, 2023; he steps down as CFO.","Tammy Furlong, previously VP of Finance, appointed CFO effective July 12, 2023.","Ferra's base salary increased to $600,000, target bonus 50%, and options for 35,000 shares.","Furlong's base salary increased to $430,000, target bonus 40%, and options for 53,433 shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-011852","json":"https://secwatch.observer/filing/0001558370-23-011852.json","markdown":"https://secwatch.observer/filing/0001558370-23-011852.md","text":"https://secwatch.observer/filing/0001558370-23-011852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783032/000155837023011852/0001558370-23-011852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783032/000155837023011852/elev-20230712x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:50:29.605632+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3e5b4e7294","claim":"Joseph J. Ferra, Jr. was appointed as President and Chief Executive Officer at Elevation Oncology, Inc..","evidence_excerpt":"appointed Joseph J. Ferra, Jr. as (i) President and Chief Executive Officer of the Company and (ii) a member of the Board, to serve as a Class I director with an initial term expiring at the Company’s 2025 Annual Meeting of Stockholders, in each case, effective as of July 12, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783032/000155837023011852/0001558370-23-011852-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"d94ae4972e","claim":"Joseph J. Ferra, Jr. was appointed as member of the Board at Elevation Oncology, Inc..","evidence_excerpt":"appointed Joseph J. Ferra, Jr. as (i) President and Chief Executive Officer of the Company and (ii) a member of the Board, to serve as a Class I director with an initial term expiring at the Company’s 2025 Annual Meeting of Stockholders, in each case, effective as of July 12, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783032/000155837023011852/0001558370-23-011852-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"member of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}